Transitioning Investigator Award Recipient: Marjorie Gondre-Lewis, PhD

Linking Genetic Risk for Addiction and HIV Pathology

January 9, 2019

Dr. Gondre-Lewis
The District of Columbia (DC) suffers from the highest rate of human immunodeficiency virus (HIV) infection per 100,000 in the United States. DC also has a high rate of drug abuse and addiction. When people take drugs like heroin, cocaine, cigarettes, marijuana, alcohol, and others, they are more likely to get involved in risky behaviors that can lead to sexually transmitted or needle infection with HIV/AIDS. In the brain, mental health disease and addiction are processed in similar regions that lead to reduced feelings of pleasure. Research shows that the same pleasure centers in the brain that are affected in addiction and in mental health disease are places where HIV likes to hide and divide. In this research, we want to figure out if the progression of brain disease in HIV is related to if a person has DNA that makes them likely to become addicted to drugs, and if this affects the way they take their HIV medicine.
 
The researchers are conducting ongoing research in African-American patients with a history of drug (heroin) abuse, and our initial studies show a relationship between DNA risk genes and their addiction history. At present, it is not known if HIV infection is linked with genetic risk for addiction, and if this risk predicts whether people will stick to their HIV medication. Some studies show that there are specific regions in the brain, related to reward, that are the targets of HIV, but we don’t know if HIV impacts the long cable connections, axon fibers, between the reward centers and other brain centers. this study will test the theory that patients with genes for addiction risk are also at increased risk for HIV infection, and that internal connection patterns of neurons in the brain of chronic drug users will correlate with HIV disease and their adherence to therapy.
 
The results of this work will be shared with the general public at soon as it is available, through Washington DC Center for AIDS Research (DC-CFAR) sponsored events, throughout the community whenever possible, in academic circles, and through research publications. This work will have the broader impact to de-stigmatize drug abuse problems in the community, and to frame it as a genetic based disease that can be targeted for treatment.